Q-omics provides the consensus-scored ADCY10 profile across patient tissues and cancer cell-line models. ADCY10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ADCY10 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADCY10 RNA expression shows 16,381 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, KIRC, and TGCT as cancer lineages where ADCY10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADCY10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADCY10 survival associations across molecular data types. ADCY10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADCY10 RNA expression–survival associations across cancer types. High ADCY10 expression shows unfavorable associations in LGG, MESO, UCEC, OV, ACC and KICH. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ADCY10 RNA expression.
This table summarizes ADCY10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADCY10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADCY10 shows higher tumor expression in KIRC, HNSC, LUSC, LIHC, LUAD and PRAD. The KIRC box plot shows higher ADCY10 RNA expression in tumor versus normal tissue (log2 FC = +0.226, t-test p < 0.001).
This table shows molecular features associated with ADCY10 in patient tissues and cancer cell lines. In patient samples, ADCY10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADCY10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
